Novavax price target lowered to $12 from $14 at BofA
BofA lowered the firm’s price target on Novavax (NVAX) to $12 from $14 and keeps a Neutral rating on the shares. The company announced ...
Why Is COVID-19 Vaccine Maker Novavax Stock Trading Lower On Wednesday?
On 1, Novavax, Inc. (NASDAQ:NVAX) and the U.K. Health Security Agency, representing the U.K. Secretary of State for Health ...
Hosted on MSN22h
Novavax, Inc. (NASDAQ:NVAX) Q3 2024 Earnings Call Transcript
Let me take a moment to highlight our progress last quarter, all of which we believe will position Sanofi for success when ...
Novavax: Balancing Potential and Risk Amid Strategic Shifts and Uncertain Market Outlook
Analyst Alec Stranahan of Bank of America Securities reiterated a Hold rating on Novavax (NVAX – Research Report), reducing the price ...
Novavax Q3 Earnings A Week Away - Time To Accept A New Reality
Besides Sanofi deal for nuvaxovid, Novavax has few opportunities to generate additional revenue, which likely means its stock ...
Novavax Reports Third Quarter 2024 Financial Results and Operational Highlights
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...
pharmaphorum1y
Novavax secures full EU approval for COVID-19 vaccine Nuvaxovid
In the first of a double dose of wins for US biotech Novavax, the company has been granted full marketing authorisation (MA) by the European Commission in the EU for Nuvaxovid (NVX-CoV2373 ...
Novavax drops as J.P. Morgan cuts to Underweight after recent rally
The deal led J.P. Morgan to upgrade the stock at the time, as the company received $500M from the French drugmaker as part of ...
Medscape27d
New Flu and Updated COVID Vaccines Greenlighted by Europe
The CHMP also recommended a revised composition for Nuvaxovid, an already approved vaccine that targets the JN.1 variant of the SARS-CoV-2 virus. The news follows recommendations by the European ...
Yahoo Finance1mon
Novavax's Updated 2024-2025 Nuvaxovid™ COVID-19 Vaccine Receives Authorization in the EU
today announced that the European Commission granted Marketing Authorization for Novavax's updated 2024-2025 Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2705), dispersion for ...